S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.
|Codexis Reports Second Quarter 2013 Results ()|
|Codexis Receives Notice Alleging Breach of Dyadic License Agreement (2013/8/5)|
|Codexis Reschedules Second Quarter 2013 Financial Results (2013/8/5)|
|Codexis Appoints Greg Hughes, Ph.D., as Vice President, Strategic Alliance & Product Development (2013/11/5)|
|Codexis Reports Third Quarter 2013 Results and Business Update (2013/11/12)|
|Codexis Named Finalist for CPhI Pharma Award for Best Innovation in Process Development (2013/10/2)|
|Celldex Therapeutics' CDX-1127 Well Tolerated and Demonstrates Anti-Tumor Activity in Phase 1 Dose-Escalation Study (2013/11/7)|
|Celldex Reports Second Quarter 2013 Financial Results (2013/8/6)|
|Celldex Reports Third Quarter 2013 Financial Results (2013/11/8)|
|Celldex Therapeutics Announces Upcoming Data Presentations at the Society for Immunotherapy of Cancer and Society of Neuro-Oncology Annual Meetings (2013/10/21)|
Click above to view more mutual fund data and stats for cdxs - Codexis, Inc..